[Special Stock] SK Bio's COVID-19 Vaccine Valued at 9.4 Trillion Won... Aiming for Emergency Use Approval Next Year

[Asia Economy Reporter Hyungsoo Park] SK Bioscience is showing strong performance. A securities firm's analysis report stating that the value of the COVID-19 vaccine candidate GBP510 reaches 9.4441 trillion KRW appears to have influenced the stock price.

At 9:44 AM on the 10th, SK Bioscience was trading at 261,500 KRW, up 12.47% from the previous day.

NH Investment & Securities forecasted that SK Bioscience will grow through investments and mergers and acquisitions (M&A) based on net cash. They also judged the likelihood of successful COVID-19 vaccine development to be high. They issued a 'Buy' rating with a target price of 280,000 KRW.

Researcher Byung-guk Park of NH Investment & Securities predicted that SK Bioscience will achieve sales of 1.0834 trillion KRW and an operating profit of 485.7 billion KRW this year.

Researcher Park emphasized, "SK Bioscience has secured an excellent track record due to COVID-19," and added, "Based on performance, they plan to invest 393.4 billion KRW over three years in expanding the Andong plant and the Songdo R&PD Center."

He said, "The market has confirmed dramatic growth over the past 1-2 years through initial order efforts, securing track records, and expansion via orders by contract manufacturing organizations (CMOs) such as Samsung Biologics and Wuxi," and added, "Samsung Biologics formed a market capitalization of 60 trillion KRW through facility investments of 3.6 trillion KRW."

Furthermore, he analyzed, "They are developing a recombinant protein COVID-19 vaccine," and "They are currently applying for global Phase 3 clinical trial approval." He also stated, "They received an investment of 200 billion KRW for Phase 3 costs from the international private organization CEPI," and "They aim for emergency use authorization in the first half of next year."

He analyzed, "Although there are concerns about market share, actual supply data shows sufficient opportunity," and "The supply contract between already approved vaccines including Moderna and COVAX is for 1 billion doses, but actual supply is at the level of 100 million doses." He also said, "Research on variants and booster shots is ongoing," and "Even with conservative assumptions, they expect to achieve annual pre-tax profits in the 400 billion KRW range."

This content was produced with the assistance of AI translation services.